ClinicalTrials.gg
Not yet recruitingNCT06077305MODESTUpdated Oct 19, 2023

A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke

An observational study in Cerebral Small Vessel Diseases and Ischemic Stroke, sponsored by Beijing Tiantan Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-19.

Sponsored by Beijing Tiantan Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Cerebral Small Vessel Diseases by Beijing Tiantan Hospital — 6 open to participants now, 7 under way, 1 of them phase 3. Cerebral Small Vessel Diseases · Beijing Tiantan Hospital.

Started
2023
with 1 other
Observational
3 of 10
2 open now
Registered
5th of 10
by date

Among the 10 studies in Cerebral Small Vessel Diseases by Beijing Tiantan Hospital, this one is one of 2 that started in 2023, is one of 3 observational ones, and was the 5th registered.

Cerebral Small Vessel Diseases

128 studies on the registry are indexed under Cerebral Small Vessel Diseases; 71 are open to participants now.

Browse Cerebral Small Vessel Diseases studies →

Open to participants now

6 of the 10 studies in Cerebral Small Vessel Diseases by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 46 Cerebral Small Vessel Diseases studies recruiting now, 26 (57%) set no upper age limit and 5 (11%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Cerebral Small Vessel Diseases by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

This study aims to construct a registry platform for microcirculatory disorders in a large sample of Chinese patients with cerebral small vessel disease and ischemic stroke; To explore the role of microcirculatory disorders in different types of cerebral small vessel disease and iachemic stroke, as well as their pathogenesis, severity, and prognosis; And to research on the drug treatment of microcirculatory disorders for cerebral small vessel disease and stroke in the real world.

Read the detailed description

Cerebral small vessel disease (CSVD) is a clinical syndrome with imaging and pathological changes, which is caused by various structural abnormality or functional dysfunction of small blood vessels including cerebral arterioles, perforating arteries, capillaries, and venules. It is also a common cause of stroke. Among people over 60 years old, the prevalence of CSVD exceeds 80%, and it is speculated that the number of CSVD patients in China exceeds 200 million, far higher than the number of stroke patients. CSVD can cause about 20% of stroke and 50% of dementia, while also doubling the risk of dementia and death, and tripling the risk of stroke. It is an important cause of death and disability in elderly people in China.

Stroke is a kind of cerebrovascular diseases characterized by sudden localized or diffuse neurological deficits caused by cerebral blood circulation disorders, and is the main clinical phenotype of cerebrovascular diseases. Stroke is characterized by high incidence rate, high disability rate, high mortality, high recurrence rate, and high economic burden. It is the first cause of death and disability in adult in China.

Microcirculatory disorders may play an important role in the pathophysiological process of ischemic CSVD. The pathological process of CSVD involves various components of the neurovascular units, including the blood-brain barrier composed of vascular endothelial cells, basement membrane, pericytes, and astrocytes, as well as oligodendrocytes, neurons, and extracellular matrix, etc.Among them, the disruption of the blood-brain barrier and endothelial damage are considered to be the initial stage of the pathological process of CSVD, causing the destruction of various secondary microcirculation structures and functions, namely the occurrence of microcirculatory disorders.

Microcirculatory disorders may also play a major role in the occurrence and development of ischemic cerebrovascular disease. By exploring multiple omics markers such as specific molecular biological markers related to ischemic cerebrovascular disease in the pathophysiological pathways of microcirculatory disorders, traditional risk factors and imaging markers can be combined to create prediction models for ineffective reperfusion of acute ischemic stroke and progression of CSVD, providing scientific evidence for improving the prognosis of acute ischemic stroke and CSVD.

03

Conditions studied

  • Cerebral Small Vessel Diseases
  • Ischemic Stroke

Keywords

  • Cerebral Small Vessel Diseases
  • Ischemic Stroke
  • Microcirculation Disorder
  • Multicenter Study
  • Registry Study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Study 1: Patients with acute ischemic stroke.

Study 2: Patients with ischemic stroke during the recovery period.

Study 3: Patients with cerebral small vessel disease based on STRIVE classification.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Study 1:

  1. Age ≥ 18 years old.
  2. Acute ischemic stroke within 7 days of onset.
  3. Sign an form.

Study 2:

  1. Age ≥ 18 years old.
  2. Ischemic stroke during recovery period, within 30 days to 1 year of onset.
  3. Sign an informed consent form.

Study 3:

  1. Age ≥ 18 years old.
  2. Within 3 years, there are characteristic lesions of cerebral small vessel disease on head MRI or CT, and they meet at least one of the following criteria:

    1. Paraventricular or deep white matter hyperintensities, Fazekas total score ≥ 2;
    2. Paraventricular or deep white matter hyperintensities, Fazekas total score=1, and at least two vascular risk factors (hypertension, hyperlipidemia, diabetes, current smoking, obesity, history of coronary heart disease, history of stroke).
    3. Paraventricular or deep white matter hyperintensities, Fazekas total score=1, with ≥ 1 lacune.
    4. New recent subcortical small infarcts.
  3. Sign an informed consent form.

Exclusion criteria

Exclusion Criteria:

Study 1:

  1. Cerebral hemorrhage and subarachnoid hemorrhage within 3 months of onset.
  2. There are untreated cerebral vascular malformations or untreated aneurysms (diameter>3mm).
  3. Confirmed neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Parkinson's syndrome, etc.
  4. A mental illness diagnosed according to the diagnostic criteria.
  5. There are clear diagnoses of non-vascular white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy, etc.
  6. Unable to cooperate in completing follow-up visits due to geographical or other reasons.
  7. The patient also participated in other clinical trials.

Study 2:

  1. Cerebral hemorrhage and subarachnoid hemorrhage within 3 months of onset.
  2. There are untreated cerebral vascular malformations or untreated aneurysms (diameter>3mm).
  3. Confirmed neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Parkinson's syndrome, etc.
  4. A mental illness diagnosed according to the DSM-V diagnostic criteria.
  5. There are clear diagnoses of non-vascular white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy, etc.
  6. Unable to cooperate in completing follow-up visits due to geographical or other reasons.
  7. The patient also participated in other clinical trials.

Study 3:

  1. Cerebral hemorrhage and subarachnoid hemorrhage within 3 months of onset.
  2. There are untreated cerebral vascular malformations or untreated aneurysms (diameter>3mm).
  3. Confirmed neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Parkinson's syndrome, etc.
  4. A mental illness diagnosed according to the DSM-V diagnostic criteria.
  5. There are clear diagnoses of non-vascular white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy, etc.
  6. Unable to cooperate in completing follow-up visits due to geographical or other reasons.
  7. The patient also participated in other clinical trials.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Registry Study on Microcirculatory Disorders in Acute Ischemic Stroke

    Establish a Chinese registry platform for microcirculatory disorders after acute ischemic stroke; use this registry platform to record the prevalence, diagnosis and treatment information, and prognosis of microcirculatory disorders after acute ischemic stroke.

  • Registry Study on Microcirculatory Disorders in Ischemic Stroke during Recovery Period

    Establish a national registry platform for microcirculatory disorders in ischemic stroke during recovery period; use this registry platform to record the prevalence, diagnosis and treatment information, and prognosis of microcirculatory disorders in ischemic stroke during recovery period.

  • Registry Study on Microcirculatory Disorders in CSVD

    Establish a national registry platform for microcirculatory disorders in CSVD; use this registry platform to record the prevalence, diagnosis and treatment information, and disease outcome of microcirculatory disorders in CSVD.

06

What researchers measure

Primary outcomes

  1. The correlation between microcirculatory disorders and recurrence of stroke (ischemic stroke and hemorrhagic stroke)

    This study will collect disease information related to microcirculatory disorders and recurrent stroke among patients with acute ischemic stroke.

    Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month

  2. Correlation between microcirculatory disorders and daily living ability levels (mRS) in patients with acute ischemic stroke

    This study will collect disease information related to microcirculatory disorders and mRS among ischemic stroke patients during recovery period.

    Time frame: baseline, 3rd month, 6th month, 12th month, 18th month, 24th month

  3. The correlation between microcirculatory disorders and cognitive function in CSVD (Mini COG).

    This study will collect disease information related to microcirculatory disorders and Mini COG among patients with CSVD.

    Time frame: baseline, 3th month, 12th month

Secondary outcomes

  1. The drug treatment of acute ischemic stroke in the real world based on microcirculation disorders.

    Record all the medication treatment information during the follow-up period since the last visit, and all the medications information is collated to describe the patient's medication regimen.

    Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month

  2. The correlation between microcirculatory disorders and the combination of vascular events (ischemic stroke, hemorrhagic stroke, myocardial infarction, vascular death) in the recovery period of ischemic stroke.

    This study will collect Major Adverse Cardiovascular Events (MACE): including ischemic stroke, hemorrhagic stroke, myocardial infarction, and vascular death.

    Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month

  3. The correlation between microcirculatory disorders and the pathogenesis of acute ischemic stroke with different etiological subtypes.

    Record the final diagnosis and main combined diagnosis of this enrollment event and complete blood laboratory examination, transcranial doppler ultrasound examination, physical examination and the like to ensure and evaluate the correlation between microcirculatory disorders and the pathogenesis of recovery ischemic stroke in different etiological subtypes.

    Time frame: baseline, 3rd month, 12th month

  4. The correlation between microcirculation disorders and the severity of acute ischemic stroke.

    This study will collect disease information related to microcirculatory disorders among patients with acute ischemic stroke to evaluate the correlation between microcirculation disorders and the severity of acute ischemic stroke.

    Time frame: baseline, 3rd month, 12th month

  5. An effective treatment method for microcirculatory dysfunction targets in acute ischemic stroke.

    Record the medication treatment information during the follow-up period since the last visit, to explore and build an effective treatment method for microcirculatory dysfunction targets in acute ischemic stroke.

    Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month

  6. The drug treatment of ischemic stroke in the recovery period based on microcirculation disorders in the real world.

    Record the medication treatment information during the follow-up period since the last visit, including antiplatelet therapy, antihypertensive therapy, lipid-lowering, hypoglycemic, vasoactive drugs, neuroprotective agents, traditional Chinese medicine, etc. Detailed records of medication types, daily dosage, and duration are required.

    Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month

  7. The correlation between microcirculatory disorders and the pathogenesis of ischemic stroke during recovery period classified by different etiological subtypes.

    Record the final diagnosis and main combined diagnosis of this enrollment event and complete blood laboratory examination, transcranial doppler ultrasound examination, physical examination and the like to ensure and evaluate the correlation between microcirculatory disorders and the pathogenesis of recovery ischemic stroke in different etiological subtypes.

    Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month

  8. The correlation between microcirculatory disorders and the severity of ischemic stroke during recovery period.

    This study will collect disease information related to microcirculatory disorders and ischemic stroke patients during recovery period to evaluate the correlation between microcirculation disorders and the severity of ischemic stroke.

    Time frame: baseline, 3rd month, 12th month

  9. An effective treatment method for microcirculatory dysfunction targets in the recovery stage of ischemic stroke.

    Record the medication treatment information during the follow-up period since the last visit, to explore and build an effective treatment method for microcirculatory dysfunction targets in the recovery stage of ischemic stroke.

    Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month

  10. The correlation between microcirculatory disorders and the outcome/prognosis of ischemic stroke during recovery period.

    This study will collect disease information related to microcirculatory disorders and mRS among ischemic stroke patients during recovery period to assess the correlation between microcirculatory disorders and the outcome/prognosis of ischemic stroke during recovery period.

    Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month

  11. The drug treatment of CSVD in the real world based on microcirculation disorders.

    Record the medication treatment information during the follow-up period since the last visit, including antiplatelet therapy, antihypertensive therapy, lipid-lowering, hypoglycemic, vasoactive drugs, neuroprotective agents, traditional Chinese medicine, etc. Detailed records of medication types, daily dosage, and duration are required.

    Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month

  12. The correlation between microcirculatory disorders and the pathogenesis of different subtypes of CSVD.

    Record the final diagnosis and main combined diagnosis of this enrollment event and complete blood laboratory examination, transcranial doppler ultrasound examination, physical examination and the like to ensure and evaluate the correlation between microcirculatory disorders and the pathogenesis of different subtypes of CSVD.

    Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month

  13. The correlation between microcirculatory disorders and the severity of CSVD.

    This study will collect disease information related to microcirculatory disorders and CSVD to evaluate the correlation between microcirculation disorders and the severity of CSVD.

    Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month

  14. Effective treatment methods for microcirculatory disorders in CSVD.

    Record the medication treatment information during the follow-up period since the last visit, to explore and build an effective treatment method for microcirculatory dysfunction targets in the CSVD.

    Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month

  15. The correlation between microcirculatory disorders and clinical symptoms of CSVD.

    This study will complete and collect relevant information of clinical symptoms and microcirculatory disorders among patients with CSVD.

    Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month

07

Study locations

1 site
08

References and documents

Publications

  • Chen Weiqi, Pan Yuesong, Chen Xia, Bai Feng, Cao Yongjun, Fan Yuhua, et al. Expert Consensus on Clinical Trial Design Standards for Cerebrovascular Disease Treatment Drugs. Chinese Journal of Stroke.2021;16:288-297
  • Hu Wenli, Yang Lei, Li Tingting, Huang Yonghua Consensus of Chinese Experts on the Diagnosis and Treatment of Cerebral small vessel disease 2021. Chinese Journal of Stroke 2021;16:716-726
  • van Veluw SJ, Shih AY, Smith EE, Chen C, Schneider JA, Wardlaw JM, Greenberg SM, Biessels GJ. Detection, risk factors, and functional consequences of cerebral microinfarcts. Lancet Neurol. 2017 Sep;16(9):730-740. doi: 10.1016/S1474-4422(17)30196-5. Epub 2017 Jul 14. PubMed 28716371 ↗
  • Debette S, Schilling S, Duperron MG, Larsson SC, Markus HS. Clinical Significance of Magnetic Resonance Imaging Markers of Vascular Brain Injury: A Systematic Review and Meta-analysis. JAMA Neurol. 2019 Jan 1;76(1):81-94. doi: 10.1001/jamaneurol.2018.3122. PubMed 30422209 ↗
  • Compilation team of the
  • De Silva TM, Faraci FM. Contributions of Aging to Cerebral Small Vessel Disease. Annu Rev Physiol. 2020 Feb 10;82:275-295. doi: 10.1146/annurev-physiol-021119-034338. Epub 2019 Oct 16. PubMed 31618600 ↗
  • Cuadrado-Godia E, Dwivedi P, Sharma S, Ois Santiago A, Roquer Gonzalez J, Balcells M, Laird J, Turk M, Suri HS, Nicolaides A, Saba L, Khanna NN, Suri JS. Cerebral Small Vessel Disease: A Review Focusing on Pathophysiology, Biomarkers, and Machine Learning Strategies. J Stroke. 2018 Sep;20(3):302-320. doi: 10.5853/jos.2017.02922. Epub 2018 Sep 30. PubMed 30309226 ↗
  • Ter Telgte A, van Leijsen EMC, Wiegertjes K, Klijn CJM, Tuladhar AM, de Leeuw FE. Cerebral small vessel disease: from a focal to a global perspective. Nat Rev Neurol. 2018 Jul;14(7):387-398. doi: 10.1038/s41582-018-0014-y. PubMed 29802354 ↗
  • Litak J, Mazurek M, Kulesza B, Szmygin P, Litak J, Kamieniak P, Grochowski C. Cerebral Small Vessel Disease. Int J Mol Sci. 2020 Dec 20;21(24):9729. doi: 10.3390/ijms21249729. PubMed 33419271 ↗
  • Uemura MT, Maki T, Ihara M, Lee VMY, Trojanowski JQ. Brain Microvascular Pericytes in Vascular Cognitive Impairment and Dementia. Front Aging Neurosci. 2020 Apr 14;12:80. doi: 10.3389/fnagi.2020.00080. eCollection 2020. PubMed 32317958 ↗
  • Low A, Mak E, Rowe JB, Markus HS, O'Brien JT. Inflammation and cerebral small vessel disease: A systematic review. Ageing Res Rev. 2019 Aug;53:100916. doi: 10.1016/j.arr.2019.100916. Epub 2019 Jun 10. PubMed 31181331 ↗
  • Shi Y, Thrippleton MJ, Makin SD, Marshall I, Geerlings MI, de Craen AJM, van Buchem MA, Wardlaw JM. Cerebral blood flow in small vessel disease: A systematic review and meta-analysis. J Cereb Blood Flow Metab. 2016 Oct;36(10):1653-1667. doi: 10.1177/0271678X16662891. Epub 2016 Aug 5. PubMed 27496552 ↗
  • Montenont E, Rondina MT, Campbell RA. Altered functions of platelets during aging. Curr Opin Hematol. 2019 Sep;26(5):336-342. doi: 10.1097/MOH.0000000000000526. PubMed 31348047 ↗
  • Hussein HM, Georgiadis AL, Vazquez G, Miley JT, Memon MZ, Mohammad YM, Christoforidis GA, Tariq N, Qureshi AI. Occurrence and predictors of futile recanalization following endovascular treatment among patients with acute ischemic stroke: a multicenter study. AJNR Am J Neuroradiol. 2010 Mar;31(3):454-8. doi: 10.3174/ajnr.A2006. Epub 2010 Jan 14. PubMed 20075087 ↗
  • Hussein HM, Saleem MA, Qureshi AI. Rates and predictors of futile recanalization in patients undergoing endovascular treatment in a multicenter clinical trial. Neuroradiology. 2018 May;60(5):557-563. doi: 10.1007/s00234-018-2016-2. Epub 2018 Mar 25. PubMed 29574600 ↗
  • Ng FC, Coulton B, Chambers B, Thijs V. Persistently Elevated Microvascular Resistance Postrecanalization. Stroke. 2018 Oct;49(10):2512-2515. doi: 10.1161/STROKEAHA.118.021631. PubMed 30355104 ↗
  • Amki ME, Wegener S. Reperfusion failure despite recanalization in stroke: New translational evidence. Clinical and Translational Neuroscience. 2021;5:2514183X2110071
  • Iadecola C, Buckwalter MS, Anrather J. Immune responses to stroke: mechanisms, modulation, and therapeutic potential. J Clin Invest. 2020 Jun 1;130(6):2777-2788. doi: 10.1172/JCI135530. PubMed 32391806 ↗
  • Feng CM, Narayana S, Lancaster JL, Jerabek PA, Arnow TL, Zhu F, Tan LH, Fox PT, Gao JH. CBF changes during brain activation: fMRI vs. PET. Neuroimage. 2004 May;22(1):443-6. doi: 10.1016/j.neuroimage.2004.01.017. PubMed 15110037 ↗
  • Diaz-Otero JM, Fisher C, Downs K, Moss ME, Jaffe IZ, Jackson WF, Dorrance AM. Endothelial Mineralocorticoid Receptor Mediates Parenchymal Arteriole and Posterior Cerebral Artery Remodeling During Angiotensin II-Induced Hypertension. Hypertension. 2017 Dec;70(6):1113-1121. doi: 10.1161/HYPERTENSIONAHA.117.09598. Epub 2017 Oct 3. PubMed 28974571 ↗
  • Reis PA, Alexandre PCB, D'Avila JC, Siqueira LD, Antunes B, Estato V, Tibirica EV, Verdonk F, Sharshar T, Chretien F, Castro-Faria-Neto HC, Bozza FA. Statins prevent cognitive impairment after sepsis by reverting neuroinflammation, and microcirculatory/endothelial dysfunction. Brain Behav Immun. 2017 Feb;60:293-303. doi: 10.1016/j.bbi.2016.11.006. Epub 2016 Nov 8. PubMed 27833044 ↗
  • Han JY, Li Q, Ma ZZ, Fan JY. Effects and mechanisms of compound Chinese medicine and major ingredients on microcirculatory dysfunction and organ injury induced by ischemia/reperfusion. Pharmacol Ther. 2017 Sep;177:146-173. doi: 10.1016/j.pharmthera.2017.03.005. Epub 2017 Mar 16. PubMed 28322971 ↗
  • Xiao Siting, Cao Chunran, Liu Hongyan, Gao Xiaoxin, Sun Yuanyuan, Zhao Jinyan, et al. Progress in pharmaceutical research on Ginkgo biloba leaf extract China Pharmaceutical. 2022;36:429-443

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2023; primary completion for Oct 2026, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2023
First posted
Oct 11, 2023
StartEst.
Oct 30, 2023
Primary completionEst.
Oct 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06077305
Responsible party
yilong Wang (Vice President of Beijing Tiantan Hospital, Beijing Tiantan Hospital) — Principal investigator
First posted
Oct 11, 2023
Start date
Oct 30, 2023 (estimated)
Primary completion
Oct 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 19, 2023

Study contacts

Yilong Wang, PhD+MD
Contact
yilong528@aliyun.com
0086-010-67092222 ext. 0
Yilong Wang, PhD+MD
principal investigator · Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion